Looks like Osmind's ketamine "me too" formulation is getting closer to FDA approval, to add to esketamine. This time via IV, rather than intranasal. ir.nrxpharma.com/news-release...

New in JAMA Network Open: Psilocybin beat the nicotine patch 4-to-1 for smoking cessation (40.5% vs 10% for prolonged abstinence). Important study and impressive headline — but what happens when you look under the hood? A thread to unpack this finding. 🧵#psychedelicscience

PIPS is hiring a Research Associate to work on clinical trials of psychedelic-assisted therapy (MDMA, psilocybin). Starting summer 2026. Great for post-bac folks looking for research experience before grad school. portlandpsychotherapy.com/behavioral-science-research-coordinator-in-portland-oregon/

I was just interviewed on the Mentally Flexible Podcast about ACT and Psychedelics. It was a fun interview and I think covered some interesting ground about shame, transcendent emotions, and psychedelic experience. Hope you enjoy it! podcasts.apple.com/us/podcast/j...

There seem to be a number of sources of data suggest that psychedelics may exert their effects through heightening positive affect and motivational systems (e.g., reward responding), not solely through dampening or reducing negative affect, which is more characteristic of antidepressants. A thread.

🧵 First clinical trial ever conducted in a state-regulated psychedelic program just published. Oregon's psilocybin program has served 20,000+ people but the majority are wealthy out-of-state travelers. This study targeted low-income participants to test feasibility. #psychedelicscience

approval to study psilocybin/COMP360 assisted therapy for PTSD we shall see if it is more effective than MDMA www.lucid.news/legislation-...

Psychedelics are FDA "breakthrough therapies" - but breakthrough for whom? New analysis reveals 85% of US psychedelic trial participants are non-Hispanic White, raising urgent questions about who actually benefits from this "revolution" in mental health. 🧵 #psychedelicscience

Important new Nature Medicine review talks about the two neuroscience mechanisms related to psychedelics that appear to be replicating across species, brain scales, and research labs. The story: Acute chaos + lasting plasticity = therapeutic change 🧵#psychedelicscience

🌿 Announcing the 2026 Perspective Psychedelic Training Retreat for healthcare professionals July 3-10, 2026 | Netherlands A week-long immersive training in psychedelic-assisted therapy grounded in ACT. Applications open now: perspectiveretreats.com/application-process

After being held in two of them as a boy, I fought for decades urging America to never again build concentration camps and put human beings in them. It breaks my heart to watch this happen twice now in my own lifetime.

🧪IMPORTANT! This graphic explains how science all over the US is funded. Congress approved a 2% increase in the #NIH budget for FY 26. Buried in the bill- Shift of ~40% of grants to MYF. This will still result in a 35% DECREASE in the NUMBER of grants funded per yr. Russel Vought is behind this.

Fun 2025 post about random facts zhengdongwang.com/2025/12/21/t...

Psychedelics don’t require ethical exemptions. We argue against “ethical exceptionalism” while supporting context-sensitive policies that uphold shared research and clinical standards. Distinctive effects ≠ new ethics. OA Link: www.researchgate.net/publication/...

Our clinical research postdoc in psychedelic science is still receiving applications through January 6th! Come join our awesome team! share.google/8eoBuA33dYa1...

Great to see some studies coming out on psilocybin for PTSD. Lots of facilitators in Oregon are using psilocybin to treat PTSD, but so far we are lacking data. Only one previous open label trial has been published that I know of. The authors just published a qualitative study from that study. A🧵

Ive seen this in papers I've reviewed. People, you can't trust the references that chatgpt generates! That's not how llms work. search.app/CRgw2

New psilocybin cognition study shows "significant improvements" in processing speed & executive function after treatment. But dig into the data and the picture gets complicated. A thread on why statistical significance does not equal clinical meaningfulness 🧵 #psychedelicscience

🐁 Very concerning finding: Psilocybin promotes brain tumour growth Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed." Extends to other serotonergic drugs like LSD.

Another article about Oregon’s psilocybin system for those interested. From my vantage point seems like the system is relatively stable but probably shrinking some from increased competition from Colorado. Fewer people from the Midwest and east coast these days.

This new @michellemonje.bsky.social preprint shows that #psilocybin promotes the rapid and persistent growth of... xenografted glioma in mice. 🫠 www.biorxiv.org/content/10.6... Enduring but maladaptive plasticity induced by #psychedelics. h/t @tylerekins.bsky.social @theborislab.bsky.social

Seems like the The "Memory Wars" are coming back - now with psychedelics. A few studies coming out, this one showing 42% of people with post-psychedelic difficulties linked them to childhood trauma. Centrally, some said they recovered memories they had NO prior recollection of. #psychedelicscience

Critical commentary on a recent paper reporting emergence of dissociated traumatic memories during psilocybin treatment now out in the Journal of Eating Disorders, with @trpwolff.bsky.social, @manojdoss.bsky.social, Lilian Kloft-Heller, and @henryotgaar.bsky.social. doi.org/10.1186/s403...

Looks like we have a 7th placebo controlled trial on microdosing psychedelics showing microdosing did not outperform placebo, this time for depression. #psychedelicscience www.linkedin.com/posts/justin...

Two more rigorous placebo-controlled trials just came out that were negative on microdosing, this time with psilocybin. I think these are the 5th and 6th RCTs with negative results. NO cognitive or mood benefits compared to placebo. 🧵 #psychedelicscience

I had missed this interesting podcast from 2023 with Matt Johnson at Johns Hopkins, talking about his history of psychedelic research and thoughts on his groundbreaking study on psilocybin-assisted therapy for smoking cessation. #psychedelicscience

A comprehensive living systematic review on psychedelics & MDMA for mental disorders just launched - this a really important new resource for tracking the evidence in real-time. #psychedelicscience

Super important new paper on reports of challenging experiences by therapists who have participated in research trials of psychedelic-assisted therapy. Reveals huge rift between what providers believe is necessary and what industry is developing as a standard. #psychedelicscience

Strongest data yet suggesting that repeated MDMA use causes deficits in declarative memory (e.g., memory for new information, words, etc). #psychedelicscience #MDMA 10.1093/brain/awaf391

New review says that after 55+ years of psychedelic research, we have very few empirical studies on music selection for psychedelic-assisted therapy—despite experts calling music central to therapeutic outcomes. #psychedelicscience

Thoughtful and well-informed op-ed from @ianlmorgan.bsky.social Definitely worth a read! www.the-scientist.com/nih-leadersh... 1/2

Interesting commentary on idea of "nondirective" approach in psychedelics as culturally laden. Researchers interviewed therapists in clinical trials and "everybody told us they were totally non-directive." #psychedelicscience

Will psychedelic researchers finally speak the same language? A new paper proposes standardized terminology for the field - and some of it is really new - Will it catch on? Here's what they want to change. #psychedelicscienceRetry

New publication 🚨 "AI and the Future of Academic Peer Review" - led by Sebastian Porsdam Mann, with @cam.ac.uk Mateo Aboy, Joel Seah, Zhicheng Lin, Xufei Luo, @biowhal.bsky.social, Hazem Zohny, Timo Minssen, and Julian Savulescu: buff.ly/kP5Y6tN

An interesting new preprint about self-compassion in psychedelics. Seeing growing research here with Gabrielle Agin-Liebes leading the way. www.researchgate.net/publication/... #psychedelicscience

🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵 www.medrxiv.org/content/10.1...

Love this new review on psychedelics & emotions from colleagues! One theme—how we measure positive emotions— resonates with our paper on why distinct positive emotions need more focus in psychedelic science, given their potential role in therapeutic benefits: www.tandfonline.com/doi/10.1080/...

New study showing that psilocybin can be given to patients on ventilators, dialysis, and with advanced heart failure. Zero serious adverse events occurred further demonstrating that psilocybin can be safe with appropriate medical monitoring. #psychedelicscience

Applications close in 10 days - don't miss out on this great opportunity! ALSO!!! another research role in our lab coming soon – please subscribe for announcement if you’re not eligible for the current one: www.monash.edu/medicine/scs...

New analysis reveals a huge disconnect in MDMA therapy pricing: Lykos wants $36,000 for the drug alone, but researchers calculate it it needs to be around $10,500 to be cost saving. This could be the difference between a niche drug for a few vs a breakthrough therapy accessible to millions.

Odds of winning NIH grants plummet as new funding policy and spending delays bite | Science | AAAS share.google/viASDaYC4l6n...

Interesting... MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study www.cambridge.org/core/journal...

The newest episode of my Research Matters Podcast it out, this time with Louis Castonguay talking about all he's learned forming and managing multiple practice research networks. He was a very entertaining and knowledgeable guest. I learned a ton. jasonluoma.com/podcast/loui... #researchmatterspod

Psychedelics use continues to increase in the USA among people over 25 years old (not for younger cohorts, with a drop in later adolescents. [from 2024 National Survey on Drug Use and Health]

I’m looking for a postdoc to join me at UCSD, ideally a clinical psychologist PhD who can deliver mindfulness interventions as well as write papers and do analyses. I have one of the world’s largest psychophysiology datasets of opioid misuse, OUD, & chronic pain. Competitive salary. DM or email.

new paper just dropped in Brain and Behaviour, with @bman1285.bsky.social and colleagues: doi.org/10.1002/brb3...

New report commissioned by Harvard reveals psychedelic training programs are in crisis. After MDMA's FDA rejection, it seems like the rush of new psychedelic trainees that was anticipated has stalled.

Many people report pain relief from psychedelics in surveys, but rigorous animal testing shows ZERO analgesic effects. This new preprint may reveal something crucial about how psychedelics might actually help with pain. www.biorxiv.org/content/10.1... #psychedelicscience

Good example of how route of administration makes a huge difference in dosing. In this study of sublingual dosing, 12mg of 5-MeO-DMT had relatively small subjective effects, but when that much is inhaled or insufflated, it has profound psychedelic effects: rdcu.be/ew4rJ

Interesting article here. suggests that lykos might not need to run another phase three study, and that mdma approval could happen within twelve months. open.substack.com/pub/ecstatic... #psychedelicscience